EUVIMEDEUVIMED entdecken
Vergleichsstudie

Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL)

Juan Martin-Torres iD, Roser Navarro-Soler iD, Judit Iglesias-Franco, María Lagarde-Sebastián, Otilia Bisbal-Pardo, David Rial-Crestelo iD, Adriana Pinto-Martínez, Maria Belén Sánchez-López, Mireia Santacreu, Laura Bermejo, Asunción Hernando iD, Rafael Rubio und 1 weitere

Journal of Antimicrobial Chemotherapy · 04.08.2026 · 81 (9)

DOI: 10.1093/jac/dkag285 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 21.08.2026. Verfasst von Juan Martin-Torres und 12 weiteren Autor:innen. Beteiligte Einrichtung: HIV Unit, Medicine Department, University Hospital 12 de Octubre, imas12, Glorieta Málaga 11, Madrid 28041, Spain. Hauptthemen laut MEDLINE: HIV Infections, Viral Load, Piperazines, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare the effectiveness of dolutegravir/lamivudine (DTG/3TC) versus bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) at Week 48 in treatment-naive adults with high baseline viral loads (≥500 000 copies/mL) and CD4+ cell count ≥200/mm3 and to assess immune recovery and safety.

Methods

We conducted a single-centre retrospective cohort study including all ART-naive people with HIV-1 (PWH) and HIV-RNA ≥500 000 copies/mL and CD4+ ≥200 cells/mm3 who initiated DTG/3TC or BIC/FTC/TAF during 2019–2024. Effectiveness was assessed as the proportion of participants achieving HIV-1 RNA <50 copies/mL at Week 48 [intention-to-treat, missing = failure (ITT, M = F)]. Immune recovery, metabolic and renal safety were evaluated through changes in CD4+ count, weight, lipid profile and creatinine. Time-to-virologic suppression was analysed using Kaplan–Meier curves and log-rank testing. Safety profile and immune recovery were conducted using Mann–Whitney U test.

Results

A total of 40 patients (52.5% on DTG/3TC, 47.5% on BIC/FTC/TAF) were included, with a high prevalence of primary HIV infection (PHI) (76.2% and 84.2%, respectively). No baseline differences were observed between groups. At 48 weeks, virologic suppression rates were 90.5% (19/21) in the DTG/3TC group and 94.7% (18/19) in the BIC/FTC/TAF group (log-rank P = 0.73). Viral decay kinetics were similar between groups. No virologic failures with resistance or treatment discontinuations were observed. Median CD4+ gains were comparable between groups (385 vs 243 cells/mm3; P = 0.30). No significant differences in weight gain, lipid profile, or creatinine levels were observed.

Conclusions

In ART-naive PWH with HIV-RNA ≥500 000 cp/mL and CD4+ ≥200/mm3, including those with PHI, DTG/3TC and BIC/FTC/TAF showed similar effectiveness and comparable safety profiles at Week 48.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsViral LoadPiperazinesHeterocyclic Compounds, 3-RingOxazinesLamivudineAnti-HIV AgentsEmtricitabineHumansPyridonesRetrospective StudiesHIV-1FemaleDolutegravirCD4 Lymphocyte CountMaleAdultTenofovirMiddle AgedTreatment OutcomeAdenineAntiretroviral Therapy, Highly ActiveAmidesDrug CombinationsRNA, ViralAlanine

Substanzen

PiperazinesPyridonesHeterocyclic Compounds, 3-RingOxazinesLamivudineAnti-HIV AgentsEmtricitabineDolutegravirTenofovirbictegravir

Autor:innen und Institutionen

  • HIV Unit, Medicine Department, University Hospital 12 de Octubre, imas12, Glorieta Málaga 11, Madrid 28041, Spain.
  • Intensive Care Unit, University Hospital La Princesa, Madrid, Spain.
  • Centre for Biomedical Research in Infectious Diseases Network, CIBER of Infectious Diseases (CIBERINFEC), Madrid, Spain.
  • Medicine Department, Complutense University of Madrid, Madrid, Spain.

ORCID-Profile: Juan Martin-Torres, Roser Navarro-Soler, David Rial-Crestelo, Asunción Hernando, Federico Pulido

Zitieren

APA

Martin-Torres, J., Navarro-Soler, R., Iglesias-Franco, J., Lagarde-Sebastián, M., Bisbal-Pardo, O., Rial-Crestelo, D., Pinto-Martínez, A., Sánchez-López, M. B., Santacreu, M., Bermejo, L., Hernando, A., Rubio, R., & Pulido, F. (2026). Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL). Journal of Antimicrobial Chemotherapy, 81(9). https://doi.org/10.1093/jac/dkag285

Vancouver

Martin-Torres J, Navarro-Soler R, Iglesias-Franco J, Lagarde-Sebastián M, Bisbal-Pardo O, Rial-Crestelo D, et al. Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL). Journal of Antimicrobial Chemotherapy. 2026;81(9). doi:10.1093/jac/dkag285

BibTeX
@article{MartinTorres2026,
  author = {Martin-Torres, Juan and Navarro-Soler, Roser and Iglesias-Franco, Judit and Lagarde-Sebastián, María and Bisbal-Pardo, Otilia and Rial-Crestelo, David and Pinto-Martínez, Adriana and Sánchez-López, Maria Belén and Santacreu, Mireia and Bermejo, Laura and Hernando, Asunción and Rubio, Rafael and Pulido, Federico},
  title = {Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2026},
  volume = {81},
  number = {9},
  doi = {10.1093/jac/dkag285}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche